Cimzia certolizumab pegol: Phase III data
Top-line data from the double-blind, international Phase III CIMPASI-2 trial in 227 patients with moderate to severe chronic plaque psoriasis showed that 200 and 400 mg doses of subcutaneous Cimzia every 2 weeks each met the co-primary endpoints of improving PASI 75 response rate (81.4% and 82.6%, respectively, vs. 11.6%) and of a greater proportion of patients with a >=2-point improvement in PGA to a final score of clear or almost clear (66.8% and 71.6%, respectively, vs. 2%) at week 16 vs. placebo. Patients in the low-dose cohort received 400 mg Cimzia at weeks 0, 2 and 4 followed by 200 mg every 2 weeks. By the end of 1Q17, Dermira expects to report data from the Phase II CIMPASI-1 and CIMPACT trials of Cimzia in patients with moderate to severe chronic plaque psoriasis. ...